Inhibitor of nuclear factor kappa B kinase (IKK) (IKK)

The Inhibitor of nuclear factor kappa B kinase (IKK) is a multi-subunit enzyme complex that serves as the master regulator of the NF-kappaB signaling pathway, which is central to immune and inflammatory responses (UniProt P78527, O14920). The complex typically consists of two catalytic subunits, IKK-alpha and IKK-beta, and a regulatory subunit, IKK-gamma (NEMO). Upon activation by stimuli such as pro-inflammatory cytokines or pathogens, the IKK complex phosphorylates IkappaB proteins, leading to their proteasomal degradation and the subsequent nuclear translocation of NF-kappaB transcription factors (PubMed 10485830). This translocation triggers the expression of genes involved in cell survival, proliferation, and the production of inflammatory mediators. Dysregulation of IKK is implicated in a wide range of pathologies, including chronic inflammatory diseases, autoimmune disorders, and various cancers where it promotes tumor growth and chemoresistance (PubMed 21115918). While IKK is a high-priority therapeutic target, the development of clinical inhibitors has been hindered by significant safety concerns, such as severe immunosuppression and systemic toxicity, due to the pathway's essential role in normal cellular homeostasis (StatPearls).

Other names

I-kappa-B kinaseIKK complexConserved helix-loop-helix ubiquitous kinase (CHUK)IkappaB kinase beta (IKBKB)IkappaB kinase gamma (IKBKG)NF-kappa-B essential modulator (NEMO)

Inhibition of the IKK complex prevents the phosphorylation and subsequent degradation of IkappaB proteins, thereby sequestering NF-kappaB in the cytoplasm and preventing its transcriptional activity.